Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review
Quick Take
This systematic review reaffirms Darunavir and Lopinavir as effective cornerstones of pediatric HIV management. While Lopinavir remains a global workhorse, Darunavir is increasingly prioritized for its superior resistance barrier and more favorable metabolic profile in adolescents.
💡 Clinical Impact
- Mechanistic Why: These agents inhibit HIV-1 protease, preventing the cleavage of Gag-Pol polyproteins and resulting in the production of immature, non-infectious virions. This post-translational blockade is essential for durable viral suppression.
- Clinical Benefit: Provides clinicians with "tried-and-true" salvage and first-line options. The evidence supports a predictable safety profile, allowing for clearer long-term management of immune reconstitution in pediatric patients who may face decades of antiretroviral therapy (ART).
📊 Evidence Breakdown
Evidence Grade: 🟢 8/10 (Comprehensive Systematic Review)
Analysis: The review offers a "Clean Signal" for the efficacy of these PIs. However, the data reflects a transition period in pediatric care. While Lopinavir/ritonavir (LPV/r) has the most historical data, Darunavir (DRV) demonstrates higher genetic barriers to resistance—a critical factor for adolescents struggling with adherence.
- Strengths: High-level synthesis across diverse geographical and socioeconomic cohorts.
- Limitations: Heterogeneity in Dosing. Variability in pediatric formulations (pellets vs. syrups vs. tablets) complicates the assessment of real-world efficacy and adherence-related outcomes.
Note: Long-term metabolic monitoring (lipids/glucose) remains a priority, as both agents—particularly Lopinavir—carry higher risks than modern Integrase Inhibitors.
🩺 Practice Recommendation
Status Label: [Standard of Care]
Monday Morning Action: Maintain these PIs as primary options, specifically in settings where Integrase Strand Transfer Inhibitors (INSTIs) are unavailable or contraindicated by baseline resistance.
- Preferential Selection: Where available, prioritize Darunavir over Lopinavir for adolescents to minimize metabolic side effects and benefit from a higher resistance threshold.
- Formulation Check: Ensure age-appropriate formulations (e.g., LPV/r pellets for infants) are utilized to avoid the high alcohol/propylene glycol content found in older liquid preparations.
- Adherence Counseling: Given the "pill burden" and taste issues associated with PIs, pair these prescriptions with intensive, patient-centric adherence support.